Seeing through the mist - consequences of decisions in phase II - a podcast by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry
from 2019-12-09T17:00
::
::
What's interesting about the early phase?
What are the typical decisions for phase II?
Speaking about a new indication, how do you see decisions are being made across the industry?
How should we think about phase II studies in this setting?
What statistical approaches do we have to formulate this thinking?
Further episodes of The Effective Statistician - in association with PSI
Further podcasts by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry